Vivos Therapeutics Inc (VVOS) — Titan Protect Analysis

VVOS

Vivos Therapeutics Inc

Healthcare · ·

$0.87

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$9M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.75

Based on estimated future earnings — lower means cheaper

Rev Growth

+70.5%

Year-over-year revenue change

Profit Margin

-127.7%

How much profit the company keeps from each dollar of revenue

ROE

-1,599.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$2.50

+189% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 3 analysts covering this stock

About Vivos Therapeutics Inc

Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test

https://www.vivos.com

Country: United States Employees: 270 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.096

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0442

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.467

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-42.7%

Historical annualised return based on price data

Max Drawdown

-91.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

6.21

Significantly more volatile than the market

52W High

$7.95

89% below the year high

52W Low

$0.55

59% above the year low

Avg Volume

226,273

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.14

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

61.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-128.7%

Profit from core operations before interest and tax

Free Cash Flow

$-10,076,375

Negative — the business is spending more than it generates

Revenue (TTM)

$20M

Total revenue over the last 12 months

Net Income

$-24,988,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$3.00

Target Median

$2.50

Target Low

$1.75

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go